1. Show article details.

    BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research

    GlobeNewswire – 7:00 AM ET 07/02/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that it will host an investor conference call and webcast on Thursday, July 9, 2020 at 9:00 a.m. ET to discuss the Company’s early development pipeline and research.

  2. Show article details.

    BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China

    GlobeNewswire – 6:00 PM ET 07/01/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental new drug application of BeiGene’s anti-PD-1 antibody tislelizumab for the tr...

  3. Show article details.

    BeiGene Announces Appointment of Angus Grant as Chief Business Executive

    GlobeNewswire – 7:00 AM ET 07/01/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the appointment of Angus Grant, Ph.D., as Chief Business Executive.

  4. Show article details.

    BeiGene Begins Commercializing XGEVA® (Denosumab) in China

    GlobeNewswire – 7:30 PM ET 06/30/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that it has begun commercializing XGEVA® in China for the treatment of giant cell tumor of bone.

  5. Show article details.

    BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial

    GlobeNewswire – 9:00 AM ET 06/22/2020

    Preclinical data presented at the American Association for Cancer Research 2020 Virtual Annual Meeting II. Ongoing Phase 1b/2 clinical trial on track to commence dose expansion cohorts in KRAS mutant solid tumors by the end of 2020.

  6. Show article details.

    BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China

    GlobeNewswire – 12:27 AM ET 06/19/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental new drug application of BeiGene’s anti-PD-1 antibody tislelizumab in combina...

  7. Show article details.

    BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenström’s Macroglobulinemia

    GlobeNewswire – 7:30 AM ET 06/18/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its marketing authorization application for BRUKINSA® for the treatment of patients with Waldenström’s macroglobulinemia who have received at least one prior therapy or as first-line treatme...

  8. Show article details.

    BeiGene Presents Clinical Data on Zanubrutinib and Tislelizumab at the 25th European Hematology Association (EHA) Virtual Congress

    GlobeNewswire – 2:30 AM ET 06/12/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that data on its BTK inhibitor zanubrutinib in relapsed/refractory marginal zone lymphoma and other B-cell malignancies and its anti-PD-1 antibody tislelizumab in R/R NK/T-cell lymphomas were pres...

  9. Show article details.

    BeiGene to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

    GlobeNewswire – 7:30 AM ET 06/05/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Company will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020 at 8:50 a.m. ET.

  10. Show article details.

    BeiGene Announces the Approval of BRUKINSA™ (Zanubrutinib) in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma

    GlobeNewswire – 7:15 AM ET 06/03/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its BTK inhibitor BRUKINSA™ has received approval from the China National Medical Products Administration in two indications – the treatment of adult patients with chronic lymphocytic leu...

  11. Show article details.

    BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenström’s Macroglobulinemia at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program

    GlobeNewswire – 8:00 AM ET 05/29/2020

    - Additional follow-up in Phase 3 ASPEN trial continued to show clinically meaningful safety and tolerability advantages for zanubrutinib compared to ibrutinib and demonstrated favorable CR/VGPR rate- Three-year data from Phase 1/2 trial evaluating patients with WM receiving zanubrutinib treatment showed high overall response rate- Company to host investor conference call and webcast on ASCO ...

  12. Show article details.

    BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program

    GlobeNewswire – 8:00 AM ET 05/29/2020

    CAMBRIDGE, Mass. and BEIJING, China, May 29, 2020 -- BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced results from a Phase 3 clinical trial evaluating its anti-PD-1 antibody tislelizumab in combination with standard chemotherapy for the first-li...

  13. Show article details.

    BeiGene to Host Investor Conference Call and Webcast to Discuss Clinical Study Results Presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program

    GlobeNewswire – 4:05 PM ET 05/26/2020

    CAMBRIDGE, Mass. and BEIJING, China, May 22, 2020 -- BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Company will host an investor conference call and webcast on Friday, May 29, 2020 at 8:00 p.m. ET to discuss clinical study results pr...

  14. Show article details.

    Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab

    GlobeNewswire – 2:00 AM ET 05/26/2020

    – Collaboration to explore multiple solid tumor cancer indications – – Initial development focused on multi-cohort trials in the U.S., Europe, China and Australia – LONDON and CAMBRIDGE, Mass. and BEIJING, China, May 26, 2020 -- Hutchison China MediTech Limited (HCM) and BeiGene, Ltd. (BGNE) today announced that they have entered into a clinical collaboration agreement to evaluate the safety, tole...

  15. Show article details.

    BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and Acceptance of New Drug Application for BTK Inhibitor BRUKINSA™ (zanubrutinib) in Israel

    GlobeNewswire – 7:00 AM ET 05/21/2020

    CAMBRIDGE, Mass. and BEIJING, China and PETACH TIKVA, Israel, May 21, 2020 -- BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and Medison Pharma Ltd., a leading global commercial partner for biotech and pharma companies that operates in Israel, Canada, and Cen...

  16. Show article details.

    BeiGene to Present at the Bernstein 36th Annual Strategic Decisions Conference

    GlobeNewswire – 7:00 AM ET 05/20/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Company will present at the Bernstein 36th Annual Strategic Decisions Conference on Wednesday, May 27, 2020 at 8:00 a.m. ET.

  17. Show article details.

    BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II

    GlobeNewswire – 7:00 AM ET 05/15/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical data on its investigational anti-PD-L1 antibody BGB-A333 and preclinical data on three early-stage drug candidates will be presented at the 2020 American Association for Cancer Resea...

  18. Show article details.

    BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress

    GlobeNewswire – 9:00 AM ET 05/14/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical and non-clinical data on BTK inhibitor BRUKINSA™ and clinical data on anti-PD-1 antibody tislelizumab will be presented in an oral presentation and eight posters at the 25th European...

  19. Show article details.

    BeiGene Reports First Quarter 2020 Financial Results

    GlobeNewswire – 4:05 PM ET 05/11/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today reported recent business highlights, anticipated upcoming milestones, and financial results for the first quarter of 2020.

  20. Show article details.

    BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting

    GlobeNewswire – 5:00 PM ET 04/29/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical data on its BTK inhibitor BRUKINSA™ and its anti-PD-1 antibody tislelizumab will be presented in an oral presentation and three posters at the 2020 American Society of Clinical Oncol...

Page:

Today's and Upcoming Events

  • Aug
    12

    BGNE to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    11

    BGNE announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.